ARTICLE | Clinical News
BXT-51072: OXIS will start a Phase I safety and tolerance study in volunteers.
June 17, 1996 7:00 AM UTC
Oxis International Inc. (OXIS), Portland, Ore. Product: BXT-51072, small molecule glutathione peroxidase mimic Indication: Inflammatory bowel disease Status: OXIS will start a Phase I safety and tol...